← back to search

Maaike A. van der Aa

Radboud University Nijmegen · NL
Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, Cervical Cancer and HPV Research, and PARP inhibition in cancer therapy.
h-index
34
citations
4,160
works
202
NIH funding
primary concept
Medicine
email

Recent publications

Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes.
2026cited by 0position: contributordoi
Effect of uterine manipulator on oncologic outcome in early-stage, low-grade endometrial cancer.
2025cited by 2position: contributordoi
Patient Voices: What Can We Learn From the Covid-19 Pandemic About Follow-Up Care in Gynaecologic Oncology?
2025cited by 1position: contributordoi
Radical hysterectomy or chemoradiotherapy for clinically early-stage cervical cancer with suspicious lymph nodes on imaging: a retrospective cohort study.
2025cited by 1position: contributordoi
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i> -deficient tubo-ovarian high-grade serous carcinoma
medRxiv 2025cited by 0position: middledoi
Impact of patient characteristics on primary treatment approach of endometrial cancer: a population-based study in the Netherlands.
2025cited by 0position: contributordoi
Diagnostic accuracy of MRI, CT, and [&lt;sup&gt;18&lt;/sup&gt;F]FDG-PET-CT in detecting lymph node metastases in clinically early-stage cervical cancer - a nationwide Dutch cohort study.
2024cited by 17position: contributordoi
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”
Journal of Gynecologic Oncology 2024cited by 16position: middledoi
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
2024cited by 12position: contributordoi
The cancer burden in the oldest-old: Increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019.
2024cited by 8position: contributordoi
Outcomes of patients with early stage mucinous ovarian carcinoma: a Dutch population-based cohort study comparing expansile and infiltrative subtypes.
2024cited by 7position: contributordoi
Survival of Women with Advanced Stage Cervical Cancer: Neo-Adjuvant Chemotherapy Followed by Radiotherapy and Hyperthermia versus Chemoradiotherapy.
2024cited by 3position: contributordoi
Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer with a horizontal spread of > 7 mm.
2024cited by 2position: contributordoi
Development and Internal Validation of Nomograms for Survival of Advanced Epithelial Ovarian Cancer Based on Established Prognostic Factors and Hematologic Parameters.
2024cited by 2position: contributordoi
Treatment Strategies Guided by [18F]FDG-PET/CT in Patients with Locally Advanced Cervical Cancer and [18F]FDG-Positive Lymph Nodes.
2024cited by 2position: contributordoi
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
2023cited by 32position: contributordoi
The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
2023cited by 12position: contributordoi
Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.
2023cited by 11position: contributordoi
A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
2023cited by 7position: contributordoi
Case-mix adjustment to compare hospital performances regarding complications after cytoreductive surgery for ovarian cancer: a nationwide population-based study.
2023cited by 6position: contributordoi
Impact of Sepsis on the Oncologic Outcomes of Advanced Epithelial Ovarian Cancer Patients: A Multicenter Observational Study.
2023cited by 3position: contributordoi
Incidence of gynaecological cancer during the COVID-19 pandemic: A population-based study in the Netherlands.
2023cited by 3position: contributordoi
Vulvar squamous cell carcinoma in women 80 years and older: Treatment, survival and impact of comorbidities.
2023cited by 2position: contributordoi
Evaluation of external validity of the OVHIPEC-1 trial in a real-world population.
2023cited by 1position: contributordoi
The effect of intrauterine manipulator on oncological outcome in early-stage, low-grade endometrial cancer: A retrospective cohort study
2023cited by 0position: contributordoi
Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using <scp>GLOBOCAN</scp> 2020
International Journal of Cancer 2022cited by 279position: middledoi
Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020.
2022cited by 187position: contributordoi
Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study.
2022cited by 86position: contributordoi
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.
2022cited by 31position: contributordoi
Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
2022cited by 27position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Ruud L. M. Bekkers · Center for Human Reproduction16 papers (2019–2025)Roy FPM Kruitwagen · Maastricht University Medical Centre10 papers (2019–2024)Jacobus van der Velden · Centrum voor Gynaecologische Oncologie Amsterdam6 papers (2021–2025)Hans H. B. Wenzel · Netherlands Comprehensive Cancer Organisation (IKNL)6 papers (2020–2025) · 5 papers (2020–2025)Cor D. de Kroon · Ludwig-Maximilians-Universität München3 papers (2020–2023)Joost Bart · University Medical Center Groningen3 papers (2022–2023) · 3 papers (2019–2022)Toon Van Gorp · QIMR Berghofer Medical Research Institute3 papers (2019–2022) · 3 papers (2022–2025)Maite Timmermans · Alberta Health Services3 papers (2019–2020)Anna K. L. Reyners · University Medical Center Groningen3 papers (2019–2022)Ester P. Olthof · Amsterdam UMC Locatie AMC3 papers (2022–2025)Lilian van Wagensveld · Maastro Clinic3 papers (2022–2024)Koen Van de Vijver · Ghent University Hospital3 papers (2019–2022)Jacques Ferlay · Centre International de Recherche sur le Cancer2 papers (2022–2022)Freddie Bray · Centre National de la Recherche Scientifique2 papers (2022–2022)Hans W. Nijman · University Medical Center Groningen2 papers (2020–2025)Gilles Freyer · Eau de Paris (France)2 papers (2024–2024)Gabe S Sonke · Borstkanker Onderzoek Groep2 papers (2019–2024)